pembrolizumab
Merck
['rcc,(-irccs),(-srcc),(-urcc)']
#asco22 i think this is the future! easier to justify toxicity in patients with mrd than adjuvant all comers. hope we are getting better at finding those patients in rcc. #kn564 
Medical oncologist with focus on kidney cancer, immunotherapies and the tumor microenvironment. Views expressed are my own. #kidneycancer #immunotherapy